key: cord-0279414-47paeja7
authors: Milheiro Silva, T.; Garcia, A. M.; Gouveia, C.; Candeias, F.; Brito, M. J.
title: CORONAVIRUS DISEASE 2019 IN A TERTIARY PEDIATRIC CENTER IN PORTUGAL
date: 2021-08-22
journal: nan
DOI: 10.1101/2021.08.16.21262100
sha: 9be724f0d0b48095943a438ad4e1c0a42f62798a
doc_id: 279414
cord_uid: 47paeja7

Objectives. Describe the demographic, clinical, laboratory, and imaging features of SARS-CoV-2 infected children at a tertiary pediatric center in Portugal during the first 6 months of the COVID-19 pandemic. Design. Single center, descriptive study of pediatric patients, who had a confirmed SARS-CoV-2 infection from March 7 to September 20, 2020. Setting. Tertiary Pediatric referral center. Patients. 18 years or younger. Main outcome measures. Incidence, mortality, age of infection, clinical characteristics, treatment prescribed and outcome. Results. A total of 300 patients were included with a median age of 5 years (IQR 1-11) and in 67% a contact was identified (co-habitant in 52.7%). 56 (18.7%) had pre-existing medical conditions. A mode of three days mediated symptom appearance to diagnose. The most common symptoms were fever (55.7%), cough (38.3%), and nasal congestion (24%). 23% of the patients were admitted due to complications related to COVID-19 and 2% required intensive care. We used drugs with antiviral activity in 9% of the patients, immunomodulatory medication with corticosteroids in 3.3%, and intravenous immunoglobulin in 1.7%. Two (0.6%) children died and 2.3% reported short-term sequelae. Conclusions. COVID-19 is usually a mild disease in children, but a small proportion of patients develop severe and critical disease. Fatal outcomes were rare overall and exclusive of severe previous medical conditions. Suspecting and diagnosing COVID-19 in children based on their symptoms without epidemiologic information and virus testing is very challenging. Our data also reflect the uncertainties regarding specific treatment options, highlighting that additional data on antiviral and immunomodulatory drugs are urgently needed.

A total of 300 patients were included with a median age of 5 years and in 67% a contact was identified (co-habitant in 52.7%). 56 (18.7%) had pre-existing medical conditions. A mode of three days mediated symptom appearance to diagnose. The most common symptoms were fever (55.7%), cough (38.3%), and nasal congestion (24%). 23% of the patients were admitted due to complications related to COVID-19 and 2% required intensive care. We used drugs with antiviral activity in 9% of the patients, immunomodulatory medication with corticosteroids in 3.3%, and intravenous immunoglobulin in 1.7%. Two (0.6%) children died and 2.3% reported shortterm sequelae.

Conclusions. COVID-19 is usually a mild disease in children, but a small proportion of patients develop severe and critical disease. Fatal outcomes were rare overall and exclusive of severe previous medical conditions. Suspecting and diagnosing COVID-19 in children based on their symptoms without epidemiologic information and virus testing is very challenging. Our data also . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 reflect the uncertainties regarding specific treatment options, highlighting that additional data on antiviral and immunomodulatory drugs are urgently needed.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Coronavirus disease 2019 , caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 , was first found linked to a cluster atypical pneumonia in Wuhan, China in December 2019 2 . Person to person transmission has resulted in the rapid spread of the disease across borders and continents. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020 3 , and as of September 2020, 30,675,675 cases have been confirmed and 954,417 fatal cases have been reported 4 . Europe has been one of the most affected regions 4 .

In Portugal, the first case was reported on March 2 5 and the first pediatric case on March 7. Until September 20, there were a total of 68,577 cases 6 . Of these, 6,356 were children younger than 19 years (9.3% of total cases) 6 .

Our hospital was one of two national reference hospitals for COVID-19 pediatric patients 7 and has been responsible for the management of a major portion of pediatric severe cases in our country.

An unprecedented amount of scientific information has been produced in a short amount of time 8 . This led to frequent changes in treatment strategies of COVID-19 patients. Hydroxychloroquine, for example, changed from being one of the most promising drugs 9 to being removed from the SOLIDARITY trial 10 .

Although the pediatric population seems to be less affected than adults 11 and the clinical presentation and evolution generally less severe, critical cases occur nonetheless [12] [13] [14] [15] [16] . With the increasing number of new diagnoses in Europe, severe cases in children are bound to rise, including multisystem inflammatory syndrome associated with COVID-19 (MIS-C) 17 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 COVID-19 in the pediatric ages continues to be less characterized than in adults 18 . Aspects such as secondary transmission, ideal methods for diagnosis, and clinical and laboratory markers of worse prognosis are still being questioned 19 . In addition, the pulmonary imagological aspects can be different than in the adult population 20 and therapeutic options are still limited 21 .

This study aimed to review and analyze the demographic, clinical, laboratory, and imaging features of the first SARS-CoV-2 infected patients accompanied in our hospital during the first 6 months of the pandemic.

Single center, descriptive study of children and adolescents, 18 years or younger, who had a confirmed SARS-CoV-2 infection from March 7 to September 20, 2020. Age, sex, underlying disease, date of diagnosis, route of exposure, clinical, laboratory, and radiographic findings, treatment, and outcome were analyzed. The cases were diagnosed by real-time reverse transcription-polymerase chain reaction (rRT-PCR) in a combined nasopharyngeal and oropharyngeal swab or respiratory secretions or by the confirmation of antibodies to SARS-CoV-2.

Patients were considered to have mild, moderate, severe, or critical disease according to the WHO guidelines 22 (Table 1) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint ARDS -Acute respiratory distress syndrome; cpm -cycles per minute; SpO 2peripheral capillary oxygen saturation All antiviral therapies were administered after informed consent was signed by parents or caretakers and approval by the pharmacy commission of our hospital was obtained.

The differences between the groups were assessed through univariable analysis using the chi-square test or Fisher exact probability test for categorical variables. P-values of <0.05 were considered statistically significant. Odds ratio (OR) and 95-Confidence Intervals were calculated to estimate how each factor influenced the assessed risks. All of the analyses were conducted in Stata® version 14.1.

No Patients or Public were involved in the execution of this study.

Without Acute respiratory distress syndrome (ARDS), sepsis, septic chock . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint Three hundred patients were included. May was the month with a higher count of new diagnoses (27%), accompanying, with some delay, the Portuguese epidemiologic curve (Figure 1 ). The median age was 5 years (IQR 1-11), 24.3% were younger than 1 year, and 4% younger than one month, with a male to female ratio of 1.11 (Table 2) . A known contact was identified in 67% patients.

The most common source of infection was a household contact (52.7%): 41% had at least one parent infected and 11.7% another adult co-habitant. In 4.3%, infection was nosocomial.

Fifty-six (18.7%) patients had a pre-existing chronic medical condition: chronic pulmonary disease (18), congenital heart disease (9), chronic neurologic disease (7), chromosomal abnormalities (5) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint Fever was more common in children below 5 years of age. Dyspnea, tachycardia, tachypnea, and hypoxemia were more frequent in younger children (<1year), while odynophagia, headache, myalgia, anosmia, ageusia, and thoracalgia were more frequent in older children and adolescents. Cough and rhinorrhea occurred equally in all age groups. Thirty-five patients (11.7%) with gastrointestinal symptoms presented no respiratory symptoms, although the majority (20/35) also presented fever.

The mode interval of the time between symptom appearance and diagnosis was three days (IQR 1-4).

One hundred and seventeen (39%) patients were admitted, 69 (59%) with COVID-19 and 48 (41%) for other reasons, namely diagnosis during the containment phase (6,8%), social motives (1.7%), and other conditions requiring hospitalization not related to COVID-19 (32.5%) such as surgical conditions, infections with need of IV antibiotics and psychiatric conditions. Admitted patients with COVID-19 were classified as having a mild disease in 27 cases (39.1%), moderate in 21 (30.4%), severe in 10 (14.5%), and critical in 11 (15.9%) (Table 3) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint [lobar pneumonia (2), pleural effusion (2), and lymphadenopathy (1)].

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Six patients were admitted to the PICU with an average length of stay of 10 days: MIS-C patients who needed inotropic support and mechanical ventilation

(2), myocarditis in patients with known cardiopathy (2), COVID-19 pneumonia and ARDS in a patient with lymphangioendotheliomatosis, and another patient with chronic respiratory insufficiency.

Antiviral therapy was proposed for 21 (20.4%) patients, including mild disease with comorbidities (3) moderate (5), severe (6), and critical (7) disease.

Hydroxychloroquine (HCQ) was administered in 13 (18.8%) patients, in monotherapy (8) or combined with lopinavir/ritonavir (LPV/r) (5). LPV/r was administered in four patients in monotherapy. Five (7.2%) patients were treated with remdesivir. Children admitted due to mild illness without risk factors (23.2%) did not receive therapy. In mild disease with preexisting medical conditions (15.9%), therapy was decided on a case-by-case basis. Regarding moderate disease (30.4%), sixteen patients (21.7%) did not receive antiviral treatment due to favorable clinical evolution. The other cases of pneumonia (5) were treated with HCQ (1), LPV/r (2), and HCQ combined with LPV/r (2).

Patients with hypoxemic pneumonia with severe signs of respiratory distress (10; 14.5%) were treated with HCQ (3), and HCQ combined with LPV/r (3). Four patients with severe disease did not receive treatment according to clinical evolution. Critical cases (11) included sepsis in patients with less than three . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint months of age treated with LPV/r (2) and one patient with ARDS received HCQ.

Remdesivir was administered in three patients with myocarditis and one in a child with ARDS. Four patients with MIS-C and one case of severe ARDS were treated with intravenous immunoglobulin and systemic corticosteroids. Systemic corticosteroids were still administered in the exacerbation of asthma (4) and one patient with chronic respiratory insufficiency.

Antibiotics were used in 30 (43.5%) patients. Ceftriaxone, amoxicillin with clavulanate, cefuroxime, and/or clindamycin when respiratory bacterial superinfection was suspected (17) Adverse drug reactions were seen in three patients who received LPV/r with nausea and vomiting, but with no need to discontinue therapy. Among the 13 patients who received HCQ, regular electrocardiograms were undertaken and only two had to discontinue HCQ temporarily (24 hours) due to prolonged QT interval (QTc) > 500 msec. No adverse effects were seen with remdesivir.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 The mean hospital duration of stay was 6.8 days, ranging from 1 day to 28 days.

Two patients (0.7%) had a fatal outcome, both with severe comorbidities (neurologic disease and congenital cardiopathy).

The mean duration time between the first positive and the first negative rRT-PCR was 23 days, with a range of 1 and 115 days.

Seven children (2.3%) reported sequelae: increased oxygen therapy in an infant with bronchopulmonary dysplasia (1); myocardial scar tissue in cardiac magnetic resonance (1), worsening of cardiac function in a child with severe aortic valve regurgitation (1), and weight loss and muscular atrophy in patients with MIS-C (4). A child with dilated cardiomyopathy and myocarditis showed worsening of myocardial function, thereby requiring heart transplantation.

The COVID-19 pandemic has placed a high burden on the medical community 24 .

To our knowledge, this is the largest series of pediatric patients in Portugal, and one of the largest in Europe. We are a tertiary, referral center for pediatric patients and, as such, the study population represents individuals at the more severe disease spectrum.

Children at any age are at risk of being infected [12] [13] [14] [15] [16] [17] 25, 26 . In our population, the median age was 5 years, in concordance with the ptbnet group study of European pediatric patients 15 , although lower than the CDC MMWR (11 years) 13 and Dong et al. in China (10 years) 12 and higher than the CONFIDENCE study (3.3 years) 25 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 In our study, the most common source of infection was a household member (52.7%) in concordance with other published data 15, 25 . These numbers are lower than large series from China and the United States, 76.6 16 and 91.3% 13 , respectively. In our sample, there was also a significant number of children with unknown exposition (33%). This brings to light the potential role of asymptomatic, non-diagnosed patients in the transmission of the virus in the community 27 , outside the house environment, and the need for the mass testing of the general population 28 . The rates of asymptomatic children have varied from 4.4-23% 12, 13, [15] [16] 25 and probably represent a significant underestimation as many asymptomatic children are not screened. In our population, these asymptomatic patients represent co-habitants of infected people and patients who were diagnosed during hospital pre-admission screening or during control of nosocomial transmission.

The most common presentation in our population was fever (55.7%), cough (38.3%), and coryza (24%) unlike other studies 12, 13, 15, 16 Anosmia, a common symptom in adults 29 , has been referred to in 3.6% of our patients. Probably this represents an underreport since anosmia is difficult to elicit in younger children 30 . Patients with gastrointestinal signs and no respiratory symptoms represented 11.7%. This points to the fact that children with no respiratory symptoms must also be screened 15 . The mean interval of time between symptom appearance and diagnosis was 3.2 days. This is similar to the other published pediatric series 31 .

We had a hospital admission rate of 39%. Patients younger than 1 year, presenting with respiratory distress signs and those with pre-existing medical conditions, were significantly more likely to be admitted. The high admission . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 rate reported relates to the fact that we function as a referral center for the entire south area of the country.

Respiratory viral coinfection occurred in 16.2% of the COVID-19 admitted patients. This is a lower number than what has been previously reported 32 . The increased use of masks and the quarantine measures instituted (e.g. closing of schools) probably explains this discrepancy 33 .

In children with SARS-CoV-2, treatment primarily consists of supportive care, including oxygen and advanced respiratory support, hydration, nutritional support, and antipyretics 34 . A various number of drugs have been proposed as treatment options in children and their use has been reported and encouraged by the national guidelines 15 . Some of them have, since the beginning of the pandemic, been withdrawn from regular clinical use 10 . Examples are lopinavir/ritonavir, which was proposed to act through the inhibition of SARS-CoV-2 proteinases 35 . It was stopped due to the lack of proven efficacy and concerns regarding its pharmacodynamics 10 , and hydroxychloroquine, proposed for the inhibition of SARS-CoV-2 entry into cells and host immunomodulatory effects 36 , which was stopped due to the lack of proven efficacy and the concern about the relevant side effects (QTc prolonging effect, arrythmias) 37 . Remdesivir has emerged as the preferred agent for treating severe COVID-19 in children 33, 38 . Our data reflects the uncertainties regarding drug treatment options for COVID-19 since the beginning of the pandemic. Immunomodulatory therapy is reserved for patients with evidence of hyperinflammation 39 . In addition, patients with known asthma or airway hyperreactivity should continue their inhaled corticosteroid and, in case of exacerbation, systemic steroids should be considered.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Infection of the respiratory system and endothelial cells by SARS-CoV-2 causes an intense inflammatory response that includes the activation of the hemostatic system 40 . As such, enoxaparin should be considered in patients with MIS-C and/or patients with other known risk factors for thrombosis 41 .

Rare pediatric fatal cases have been reported 15 . In our study, both fatal cases had severe pre-existing medical conditions. In our study, seven children (2.3%) reported sequelae. However, these are probably underrated. It does not include, for example, psychological sequelae.

Exercise intolerance, reduced lung vital capacity, myocardial scars in MIS-C patients, and loss of muscle mass are just some of the possible sequelae that need to be identified as soon as possible 42 .

Our findings add to the general feeling that COVID-19 is usually a mild disease in children, but a small proportion of patients develop severe and critical disease.

Suspecting and diagnosing COVID-19 in children based on their symptoms without epidemiologic information and virus testing is very challenging. A significant proportion of patients is likely to be asymptomatic and the only way of diagnosing those patients is mass testing in the community.

Uncertainty still remains regarding specific antiviral options as more robust studies are bound to arrive in the near future.

We hope our study clearly details our experience with these patients and adds to the general information of this global health problem.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 What is known about this topic -COVID-19 is usually a mild disease in children, but a small proportion of patients develop severe and critical disease.

-Suspecting and diagnosing COVID-19 in children based on their symptoms without epidemiologic information and virus testing is very challenging.

-COVID-19 in pediatric ages continues to be less characterized than in adults.

-Suspecting and diagnosing COVID-19 in children based on their symptoms without epidemiologic information and virus testing is very challenging.

-A significant proportion of patients is likely to be asymptomatic and the only way of diagnosing those patients is mass testing.

-Our data reflects the uncertainties regarding drug treatment options for COVID-19 since the beginning of the pandemic.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint Available from: https://covid19.min-saude.pt/ponto-de-situacao-atual-emportugal/ . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint systematic review of imaging findings. Pediatr Radiol. 2020; 50 (9) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Plano Nacional de Preparação e Resposta à doença por novo coronavírus (COVID-19)

Characteristics of scientific articles on COVID

10 -World Health Organization. News release: "WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Epidemiology of COVID-19 among children in China

Morb Mortal Wkly Rep. Department of Health and Human Services; the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

SARS-COV-2 infection in children and newborns : a systematic review

Article number: 158 (2020) 20 -Shelmerdine SC, Lovrenski J, Caro-Domínguez P, Toso S and Collaborators of the European Society of Paediatric Radiology Cardiothoracic Imaging Taskforce. Coronavirus disease 2019 (COVID-19) in children: a guidance

the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications

Meta-analysis, and Rapid Guidance

Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

diagnosis in the Portuguese population . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101/2021.08.16.21262100 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021